Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maintenance therapy in lymphoma.

Ronald Mihelic1, Jonathan Kaufman, Sagar Lonial

  • 1Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.

Clinical Lymphoma & Myeloma
|November 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy.

Cancer journal (Sudbury, Mass.)·2026
Same author

Did the Implementation of a Bye Week Decrease Injury Rates in the National Hockey League?

Orthopaedic journal of sports medicine·2026
Same author

SOHO State of the Art Updates and Next Questions: How Should We Risk Stratify and Tailor Therapy for Patients With High Tumor Burden Follicular Lymphoma? A Systematic Review.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Correction: The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma.

Experimental hematology & oncology·2026
Same author

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions.

JCO precision oncology·2025
Same author

Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy.

Journal for immunotherapy of cancer·2025

Rituximab maintenance improves survival for some non-Hodgkin lymphomas (NHL) but not all. Further research is needed to optimize maintenance strategies for NHL patients.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Trials

Background:

  • Emerging therapies increase lymphoma response rates.
  • Maintenance regimens aim to improve progression-free and overall survival for responders.
  • Ideal maintenance therapy has low toxicity, is easy to administer, and shows survival benefit.

Purpose of the Study:

  • To review existing data on interferon and rituximab maintenance therapies for non-Hodgkin lymphoma (NHL).
  • To describe the benefits and shortcomings of these maintenance strategies.
  • To identify areas for future research in NHL remission maintenance.

Main Methods:

  • Comprehensive review of Phase II and randomized trials.
  • Analysis of data on interferon maintenance therapy.

Related Experiment Videos

  • Analysis of data on rituximab maintenance therapy for various NHL subtypes.

    • Main Results:

    • Rituximab maintenance shows benefits in follicular lymphoma after CVP and in diffuse large B-cell lymphoma after CHOP induction.
    • Rituximab maintenance benefits are seen after rituximab-containing regimens at relapse and in mantle cell lymphoma after R-FCM.
    • Rituximab maintenance did not show benefits after R-CHOP induction in diffuse large B-cell lymphoma or after single-agent rituximab in mantle cell lymphoma.

    Conclusions:

    • Rituximab maintenance offers survival benefits in specific non-Hodgkin lymphoma contexts.
    • The efficacy of maintenance therapy is dependent on the lymphoma subtype and prior treatment.
    • Further studies are required to explore other agents and strategies for maintaining NHL remissions.